{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:27Z","timestamp":1740126147261,"version":"3.37.3"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,25]]},"DOI":"10.1093\/bjd\/ljad227","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T02:46:23Z","timestamp":1688525183000},"page":"503-504","source":"Crossref","is-referenced-by-count":0,"title":["Is lirentelimab the \u2018magic bullet\u2019 to fight pathological mast-cell activation in systemic mastocytosis?"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-9750","authenticated-orcid":false,"given":"St\u00e9phane","family":"Barete","sequence":"first","affiliation":[{"name":"Reference center for mastocytosis (CEREMAST) , AP-HP, GH Piti\u00e9-Salp\u00eatri\u00e8re, 47\u201383 bd de l\u2019H\u00f4pital 75013 Paris and Sorbonne Universit\u00e9, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[{"name":"Reference center for mastocytosis (CEREMAST) , AP-HP, GH Piti\u00e9-Salp\u00eatri\u00e8re, 47\u201383 bd de l\u2019H\u00f4pital 75013 Paris and Sorbonne Universit\u00e9, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"2023102707073094900_ljad227-B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2023102707073094900_ljad227-B2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"key":"2023102707073094900_ljad227-B3","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30212-1","article-title":"A useful add-on international prognostic score for \u00admastocytosis?","volume":"6","author":"Barete","year":"2019","journal-title":"Lancet Haematol"},{"key":"2023102707073094900_ljad227-B4","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case\u2013control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLOS ONE"},{"key":"2023102707073094900_ljad227-B5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"2023102707073094900_ljad227-B6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/bjd\/ljad191","article-title":"Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial","volume":"189","author":"Siebenhaar","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023102707073094900_ljad227-B7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41385-020-00336-9","article-title":"A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation","volume":"14","author":"Schanin","year":"2021","journal-title":"Mucosal Immunol"},{"key":"2023102707073094900_ljad227-B8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/all.13425","article-title":"Development and \u00advalidation\u00a0of the mastocytosis activity score","volume":"73","author":"Siebenhaar","year":"2018","journal-title":"Allergy"},{"key":"2023102707073094900_ljad227-B9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/all.12842","article-title":"Development and validation of the mastocytosis quality of life questionnaire: MC-QoL","volume":"71","author":"Siebenhaar","year":"2016","journal-title":"Allergy"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad227\/51090400\/ljad227.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/503\/52625495\/ljad227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/5\/503\/52625495\/ljad227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:08:04Z","timestamp":1698390484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/5\/503\/7219341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,5]]},"published-print":{"date-parts":[[2023,10,25]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad227","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,7,5]]}}}